Loading…
Titan Biotech (BSE 524717)₹366.40+3.94%Specialty Chemicals
In the Jun 2026 quarter (consolidated), Titan Biotech reported sales of ₹58.95 Cr, up 28.3% from Jun 2025, and net profit of ₹11.04 Cr, up 57.3% year on year. For the year to Mar 2026, sales were ₹206 Cr and net profit ₹30.10 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42.97 | 45.96 | 39.95 | 42.98 | 39.94 | 37.98 | 34.96 | 45.94 | 53.90 | 56.90 | 48.94 | 58.95 |
| Expenses | 34.90 | 34.89 | 32.88 | 34.87 | 31.92 | 32.91 | 30.88 | 37.86 | 44.88 | 45.83 | 38.86 | 46.82 |
| Operating Profit | 8.99 | 10.99 | 6.99 | 7.99 | 7.99 | 4.99 | 4.99 | 8.99 | 8.99 | 10.99 | 9.99 | 11.99 |
| OPM % | 20.0% | 23.0% | 18.0% | 19.0% | 19.0% | 13.0% | 13.0% | 19.0% | 17.0% | 19.0% | 20.0% | 21.0% |
| Other Income | 1.01 | 0.00 | 0.00 | 0.99 | 0.00 | 2.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.99 | 2.01 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.99 | 0.99 | 0.99 | 1.01 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 1.01 | 0.99 |
| Profit before tax | 7.97 | 9.97 | 5.98 | 7.98 | 6.98 | 4.99 | 4.99 | 7.98 | 8.98 | 10.96 | 9.97 | 12.97 |
| Tax % | 26.0% | 26.0% | 24.0% | 24.0% | 25.0% | 26.0% | 25.0% | 24.0% | 26.0% | 26.0% | 36.0% | 26.0% |
| Net Profit | 7.02 | 7.03 | 5.02 | 6.02 | 7.03 | 4.01 | 4.02 | 7.02 | 8.04 | 9.03 | 7.02 | 11.04 |
| EPS (Rs) | 1.57 | 1.73 | 1.20 | 1.54 | 1.61 | 1.05 | 0.97 | 1.65 | 1.87 | 2.06 | 1.62 | 2.62 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 45.97 | 52.93 | 56.95 | 64.95 | 78.88 | 142 | 124 | 144 | 164 | 156 | 206 | 219 |
| Expenses | 41.89 | 46.84 | 49.86 | 55.84 | 65.81 | 95.62 | 91.65 | 114 | 130 | 130 | 167 | 176 |
| Operating Profit | 3.99 | 4.99 | 6.99 | 8.99 | 12.99 | 46.01 | 30.97 | 29.96 | 33.95 | 24.98 | 38.94 | 41.96 |
| OPM % | 9.0% | 10.0% | 12.0% | 14.0% | 17.0% | 32.0% | 25.0% | 21.0% | 21.0% | 16.0% | 19.0% | 19.2% |
| Other Income | 1.01 | 0.00 | 0.00 | 0.99 | 1.01 | 0.00 | 1.01 | 2.01 | 2.01 | 4.01 | 4.99 | 6.02 |
| Interest | 1.01 | 1.01 | 2.01 | 2.01 | 2.01 | 2.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 0.00 |
| Depreciation | 0.99 | 1.01 | 1.01 | 1.99 | 2.01 | 1.99 | 1.99 | 2.99 | 2.99 | 3.99 | 5.01 | 3.98 |
| Profit before tax | 2.99 | 2.99 | 3.99 | 5.99 | 9.98 | 42.86 | 28.94 | 27.95 | 31.89 | 23.94 | 37.89 | 42.88 |
| Tax % | 34.0% | 35.0% | 35.0% | 30.0% | 25.0% | 26.0% | 25.0% | 25.0% | 25.0% | 25.0% | 28.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | −0.06 | 0.47 | −0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 2.01 | 2.01 | 3.01 | 4.01 | 8.03 | 32.14 | 22.09 | 25.11 | 25.11 | 22.09 | 30.10 | 35.13 |
| EPS (Rs) | 0.45 | 0.55 | 0.65 | 0.84 | 1.70 | 7.33 | 5.24 | 5.99 | 6.00 | 5.20 | 7.21 | 8.17 |
| Dividend payout % | 33.0% | 26.9% | 23.0% | 0.0% | 12.0% | 4.0% | 6.0% | 6.0% | 7.0% | 8.0% | 7.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8.02 | 8.02 | 8.02 | 8.03 | 8.03 | 8.03 | 8.03 | 8.03 | 8.03 | 8.03 | 8.03 | 8.03 |
| Reserves | 12.96 | 13.97 | 14.97 | 16.96 | 23.94 | 30.91 | 59.91 | 78.00 | 102 | 125 | 145 | 173 |
| Borrowings | 8.03 | 11.03 | 22.07 | 26.10 | 24.08 | 24.08 | 16.05 | 9.04 | 9.03 | 8.03 | 3.01 | 6.02 |
| Other Liabilities | 5.03 | 7.01 | 7.01 | 6.97 | 8.95 | 12.98 | 16.08 | 13.06 | 16.08 | 15.07 | 19.09 | 27.13 |
| Total Liabilities | 34.04 | 40.03 | 52.07 | 57.06 | 65.00 | 76.00 | 101 | 108 | 135 | 157 | 175 | 214 |
| Fixed Assets | 10.96 | 10.95 | 12.96 | 13.94 | 28.86 | 30.89 | 33.85 | 34.87 | 35.87 | 51.80 | 56.80 | 61.80 |
| CWIP | 1.01 | 5.01 | 9.01 | 13.02 | 0.00 | 0.00 | 0.00 | 4.01 | 13.03 | 3.01 | 2.01 | 2.01 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.01 | 15.02 | 28.02 | 33.02 | 60.02 |
| Other Assets | 21.07 | 24.07 | 30.10 | 30.10 | 36.14 | 45.11 | 67.22 | 65.24 | 70.22 | 74.19 | 83.20 | 90.24 |
| Inventories | 11.02 | 11.03 | 14.05 | 18.04 | 21.06 | 28.08 | 33.08 | 35.10 | 36.13 | 46.11 | 51.19 | 56.14 |
| Trade receivables | 6.02 | 6.02 | 6.02 | 8.02 | 9.03 | 12.03 | 18.07 | 16.05 | 21.05 | 19.05 | 19.05 | 23.07 |
| Cash & equivalents | 0.00 | 4.01 | 4.02 | 1.01 | 2.01 | 2.01 | 5.02 | 7.03 | 5.02 | 3.01 | 6.02 | 2.01 |
| Total Assets | 34.04 | 40.03 | 52.07 | 57.06 | 65.00 | 76.00 | 101 | 108 | 135 | 157 | 175 | 214 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −2.01 | 5.02 | 0.00 | 2.01 | 5.02 | 6.02 | 19.07 | 22.07 | 21.07 | 21.07 | 20.07 | 30.06 |
| Cash from investing activity | −2.99 | −4.99 | −8.01 | −5.99 | −4.01 | −2.01 | −5.01 | −16.01 | −21.01 | −20.02 | −9.99 | −34.03 |
| Cash from financing activity | 2.99 | 1.99 | 8.99 | 0.00 | 0.00 | −3.99 | −10.99 | −3.99 | −1.99 | −2.99 | −8.01 | 0.00 |
| Net cash flow | −1.99 | 1.99 | 0.99 | −2.99 | 0.99 | 0.00 | 3.99 | 1.99 | −1.99 | −1.99 | 1.99 | −3.99 |
| Capex | 1.69 | 4.60 | 7.16 | 5.75 | 4.44 | 0.00 | 4.85 | 13.67 | 3.79 | 19.71 | 9.43 | 9.26 |
| Free cash flow | −3.01 | 0.00 | −6.99 | −4.01 | 0.99 | 7.99 | 13.99 | 8.01 | 8.01 | 12.01 | 12.01 | 21.01 |
| CFO / OP % | −28.0% | 142.9% | 20.9% | 42.9% | 73.9% | 61.9% | 65.0% | 93.0% | 96.9% | 84.9% | 103.0% | 101.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 58 | 47 | 44 | 49 | 52 | 54 | 46 | 48 | 53 | 42 | 44 | 40 |
| Inventory days | 134 | 118 | 155 | 202 | 236 | 259 | 177 | 206 | 179 | 208 | 242 | 212 |
| Days payable | 18 | 19 | 16 | 14 | 25 | 39 | 21 | 26 | 28 | 16 | 26 | 33 |
| Cash conversion cycle | 175 | 147 | 184 | 239 | 264 | 276 | 203 | 230 | 205 | 234 | 261 | 220 |
| Working capital days | 94 | 60 | 90 | 108 | 97 | 101 | 88 | 118 | 109 | 111 | 130 | 102 |
| ROCE % | — | 12.0% | 12.1% | 13.1% | 15.1% | 20.1% | 58.1% | 32.1% | 27.1% | 25.0% | 17.1% | 23.0% |
For the Jun 2026 quarter, Titan Biotech reported sales of ₹58.95 Cr, up 28.3% year on year and net profit of ₹11.04 Cr, up 57.3% year on year. The operating margin was 21.0%.
Titan Biotech's sales for the year to Mar 2026 were ₹206 Cr; over the last twelve months they were ₹219 Cr.
Net profit for the year to Mar 2026 was ₹30.10 Cr, and ₹35.13 Cr over the last twelve months. Earnings per share over the same trailing period were ₹8.17.
Titan Biotech reported borrowings of ₹6.02 Cr at Mar 2026, against cash and equivalents of ₹2.01 Cr.
Cash from operations was ₹30.06 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹21.01 Cr.